Back to search
FDAFDA · Food and drugs·Recall number D-0614-2023

Ceftriaxone for Injection, USP 2 grams per vial, Rx only, Mfg. for: Piramal Critical Care, Bethlehem, PA 18017, NDC 66794-214-42

Published May 24, 2023 · Recall initiated: May 15, 2023

Summary

FDA records drug Class II recall D-0614-2023, published May 24, 2023 and initiated May 15, 2023. Recalling firm: Astral SteriTech Private Ltd.; Status: Terminated; Reported quantity: 41,500 vials; Lot: All lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Astral SteriTech Private Ltd.
Distributor
Nationwide within the United States
Lot
All lots within expiry.
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Ceftriaxone for Injection, USP 2 grams per vial, Rx only, Mfg. for: Piramal Critical Care, Bethlehem, PA 18017, NDC 66794-214-42 recalled?

Yes. FDA published recall D-0614-2023 on May 24, 2023. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter